Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25]

Affiliations

¹ Royal Marsden Hospital, London and Surrey, United Kingdom. Electronic address: ian.chau@rmh.nhs.uk.
² Allgemeines Krankenhaus Wien, Vienna and Klinkum Klagenfurt am Wörthersee, Klagenfurt, Austria.
³ Hospital Jean Minjoz, Besançon, France.
⁴ Universitätsklinikum Magdeburg, Magdeburg, Germany.
⁵ Hôpital La Timone, Aix-Marseille University, Marseille, France.
⁶ Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
⁷ Asan Medical Center, Seoul, Republic of Korea.
⁸ National Cheng Kung University Hospital, Tainan, Taiwan.
⁹ Kinki University School of Medicine, Osaka-Sayama, Osaka, Japan.
¹⁰ The University of Hong Kong, Hong Kong.
¹¹ Istituto Oncologico Veneto IRCCS, Padova, Italy.
¹² Hepato-Gastroenterology and Digestive Oncology Unit, Centre Medico-chirurgical Magellan, CHU Bordeaux, France.
¹³ Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea.
¹⁴ Sutter Health California Pacific Medical Center, San Francisco, CA, USA.
¹⁵ National Cancer Center Hospital, Tokyo, Japan.
¹⁶ Eli Lilly and Company, Indianapolis, IN, USA.
¹⁷ Eli Lilly and Company, Bridgewater, NJ, USA.
¹⁸ Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.

Published Erratum

Ian Chau et al. Eur J Cancer. 2018 Sep.

. 2018 Sep:100:135-136.

doi: 10.1016/j.ejca.2018.06.002. Epub 2018 Jun 30.

¹ Royal Marsden Hospital, London and Surrey, United Kingdom. Electronic address: ian.chau@rmh.nhs.uk.
² Allgemeines Krankenhaus Wien, Vienna and Klinkum Klagenfurt am Wörthersee, Klagenfurt, Austria.
³ Hospital Jean Minjoz, Besançon, France.
⁴ Universitätsklinikum Magdeburg, Magdeburg, Germany.
⁵ Hôpital La Timone, Aix-Marseille University, Marseille, France.
⁶ Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
⁷ Asan Medical Center, Seoul, Republic of Korea.
⁸ National Cheng Kung University Hospital, Tainan, Taiwan.
⁹ Kinki University School of Medicine, Osaka-Sayama, Osaka, Japan.
¹⁰ The University of Hong Kong, Hong Kong.
¹¹ Istituto Oncologico Veneto IRCCS, Padova, Italy.
¹² Hepato-Gastroenterology and Digestive Oncology Unit, Centre Medico-chirurgical Magellan, CHU Bordeaux, France.
¹³ Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea.
¹⁴ Sutter Health California Pacific Medical Center, San Francisco, CA, USA.
¹⁵ National Cancer Center Hospital, Tokyo, Japan.
¹⁶ Eli Lilly and Company, Indianapolis, IN, USA.
¹⁷ Eli Lilly and Company, Bridgewater, NJ, USA.
¹⁸ Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.

No abstract available

Erratum for

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.
Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX. Chau I, et al. Eur J Cancer. 2017 Aug;81:17-25. doi: 10.1016/j.ejca.2017.05.001. Epub 2017 Jun 4. Eur J Cancer. 2017. PMID: 28591675 Clinical Trial.